Cullinan Oncology, Inc. — FY 2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022. The filing identifies the registrant as Cullinan Oncology, Inc.; the request metadata uses Cullinan Therapeutics, Inc.
Business context
The company is a clinical-stage oncology biopharmaceutical developer with no approved products or product-sales revenue. Its pipeline spans targeted small molecules and antibody and immune-engaging approaches. Zipalertinib is co-developed with Taiho; other programs include CLN-049, CLN-619, CLN-418, CLN-978 and CLN-617.
Financial performance and liquidity
| Metric | FY 2022 | FY 2021 |
|---|---|---|
| Revenue | $0 | $18.9 million |
| Research and development expense | $91.9 million | $57.8 million |
| General and administrative expense | $40.2 million | $29.1 million |
| Gain on sale of Cullinan Pearl | $276.8 million | — |
| Net income (loss) | $109.2 million | $(67.5) million |
| Net income (loss) attributable to common stockholders | $111.2 million | $(65.6) million |
| Net cash used in operating activities | $(126.7) million | $(43.4) million |
2022 profitability was driven by the one-time Cullinan Pearl sale, not recurring product revenue. The company reported $6.6 million of interest income, $42.1 million of income-tax expense and a $2.6 million unrealized investment loss in other comprehensive income. No operating margin is meaningful given the absence of product revenue and the material one-time gain.
At year-end, cash and cash equivalents were $156.2 million, short-term investments $311.1 million and long-term investments $80.9 million. The filing separately reports $82.8 million of long-term investments and interest receivable in its liquidity discussion; the balance sheet shows $80.9 million of long-term investments, with accrued interest included in current assets. Total assets were $561.1 million, total liabilities $26.1 million and stockholders’ equity $535.0 million. The filing does not show a conventional borrowing balance; accrued current liabilities included $0.178 million identified as convertible note and accrued interest. Management estimated available capital would fund operations into 2026, subject to assumptions and program spending.
Investing activities provided $249.0 million, principally reflecting the $275.0 million Pearl sale proceeds and marketable-security transactions. Financing activities used $25.9 million, primarily for the $33.3 million purchase of Cullinan MICA interests. The company expects further losses and cash outflows as development advances.
Material changes versus FY 2021
- Research and development expense rose $34.2 million, about 59%, as clinical, manufacturing and early-stage program work expanded. G&A rose $11.0 million, about 38%, with increased personnel and public-company costs, including $2.0 million of nonrecurring Pearl-sale costs.
- The company moved from a $67.5 million net loss to $109.2 million net income, principally because of the $276.8 million Pearl-sale gain. Operating cash use increased by $83.2 million, including $37.8 million paid for estimated taxes on the sale gain.
- The $18.9 million Zai Lab license revenue recognized in 2021 did not recur in 2022. The 2022 sale transferred worldwide zipalertinib rights outside Japan and Greater China to Taiho; Cullinan retained an option to co-commercialize in the U.S., with development costs and potential U.S. pre-tax profits shared equally.
Outlook, commentary and risks
- Zipalertinib: A pivotal Phase 2b study began in November 2022 in previously treated EGFR exon 20 insertion NSCLC. Its 100 mg fasted and 150 mg fed cohorts have stopping criteria requiring the 150 mg cohort to show superior safety and efficacy. Earlier Phase 1/2a results at 100 mg twice daily included a 41% confirmed response rate among 39 response-evaluable patients and median progression-free survival of 12 months; these are preliminary, nonrandomized data, with a May 9, 2022 cutoff. At 150 mg, more severe adverse events and dose modifications were observed, and enrollment in that earlier dose cohort was stopped.
- Pipeline milestones stated in the filing: Initial CLN-049 and CLN-619 clinical data were expected in mid-2023, and CLN-418 data in 2024. The FDA cleared the CLN-978 IND in January 2023; a Phase 1 study was planned for 2023. The CLN-617 IND was filed in February 2023, with a Phase 1 start targeted by year-end, pending clearance. These are management expectations, not guaranteed outcomes.
- Capital allocation and transactions: The company paid Harbour $25 million upfront in February 2023 for U.S. CLN-418 rights, with up to $148 million in development and regulatory milestones, up to $415 million in sales milestones and tiered royalties up to the high teens. The 2022 Pearl sale may also yield up to $130 million in regulatory milestones, which are contingent and not assured.
- Principal risks: Clinical efficacy and safety are unproven; patient enrollment, regulatory review and trial timing may be delayed; preliminary results may change; and the company relies heavily on third-party manufacturers and research organizations. Additional funding may be required if spending exceeds the runway estimate. Competition, intellectual-property protection, reimbursement, and the company’s relatively small workforce are also significant risks. Management reported effective disclosure controls and internal control over financial reporting; the auditor did not attest to internal-control effectiveness.
Most important facts for investors to verify
- Whether 2022 earnings and cash generation are understood in light of the nonrecurring Pearl-sale gain, related tax and sale proceeds.
- Current cash, investment balances, subsequent spending and whether the stated runway into 2026 remains supportable.
- Updated zipalertinib Phase 2b enrollment, safety, efficacy, cohort decisions and any regulatory requirements; distinguish final results from preliminary Phase 1/2a data.
- Progress, timing and results for CLN-049, CLN-619, CLN-418, CLN-978 and CLN-617, including IND and trial status.
- Terms and potential economics of the Taiho collaboration and Harbour license, including contingent milestones, cost/profit sharing and royalties.
- Share dilution and ownership: the filing reports 39,327,298 common shares outstanding and 647,500 preferred shares as of March 1, 2023; preferred shares are convertible into 10 common shares each, subject to limitations.